I PREVENT - Irbesartan In Hypertensive Diabetic Patients

Study Overview
=================
Brief Summary
-----------------
To evaluate Blood Pressure (BP) reduction to the targeted values (Systolic BP ≤ 130 mmHg and Diastolic BP ≤ 80 mmHg) in hypertensive type 2 diabetic patients. To evaluate the benefit of Irbesartan in the reduction of microalbuminuria from baseline (if any at the inclusion visit) in this population. To demonstrate the safety of Irbesartan in this population.

Official Title
-----------------
Irbesartan In Hypertensive Diabetic Patients

Conditions
-----------------
Hypertension

Intervention / Treatment
-----------------
* Drug: Irbesartan (Aprovel)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Proven Hypertensive Type 2 Diabetic Patients with HbA1c > 6% and ≤ 10% (with or without microalbuminuria). Newly diagnosed naïve hypertensive patients (no prior treatment for hypertension). OR, Patients who were receiving antihypertensive agents (maximum two agents, including one diuretic) with blood pressure targets achieved, yet, in the investigator's opinion, those patients would benefit more from switching to the study medication. These patients will undergo a wash out period for not less than 7 days prior to enrollment. Exclusion Criteria: Severe hypertension (SBP ≥ 180 mm Hg or DBP ≥ 110 mm Hg). Patients with secondary hypertension. Patients with UAE > 200µg / min. Patients with HbA1c < 6% or > 10%. Significant chronic renal impairment (Serum creatinine > 2.0 mg/dL). Significant liver disease as shown by SGPT/SGOT (ALAT/ASAT) > 2.5 times the upper limit of the normal range. Currently pregnant or lactating females. Women of childbearing potential not protected by effective contraceptive method of birth control and/or who are unwilling or unable to be tested for pregnancy. Any patient who is in need for a combination antihypertensive therapy from the start (from the medical point of view of his/her physician). Known hypersensitivity to irbesartan, other ARBs(Angiotensin Receptor Blockers), hydrochlorothiazide, or other thiazide diuretics. Patients with malignancy during the past 5 years, known collagen disease or severe cardiac, cerebrovascular or gastric disease. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Ages Eligible for Study
-----------------
Minimum Age: 35 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Irbesartan (Aprovel)|Aprovel (150 & 300mg) & CoAprovel (300/12.5mg hydrochlorothiazide) one tablet/day per os.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reach blood pressure target in hypertensive diabetic patients i.e. 130/80 mmHg. |  | During the study conduct | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The restoration of urinary albumin excretion (UAE) rate in patients with normoalbuminuria (UAE rate < 20µg / min) |  | During the study conduct | 
| First detection of overt nephropathy (UAE rate > 200µg / min), in patients with microalbuminuria or at least 30% higher than at baseline value(on at least two consecutive occasions) |  | During the study conduct | 
| Occurrence of any side effect leading to treatment discontinuation. |  | During the study conduct |